Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients

被引:13
|
作者
Tsai, Kai-Fan [1 ,2 ]
Li, Lung-Chih [1 ,2 ,6 ]
Hsu, Chien-Ning [2 ,3 ,7 ]
Lin, Chih-Che [2 ,4 ]
Lin, Yu-Hung [2 ,4 ]
Cheng, Yu-Fan [2 ,5 ]
Wang, Chih-Chi [2 ,4 ]
Chen, Chao-Long [2 ,4 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol, 123 Da Pei Rd, Kaohsiung 833, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Dept Pharm, Kaohsiung, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Liver Transplant Ctr, Dept Surg, Kaohsiung, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung, Taiwan
[6] Kaohsiung Chang Gung Mem Hosp, Inst Translat Res Biomed, Kaohsiung, Taiwan
[7] Kaohsiung Med Univ, Sch Pharm, Kaohsiung, Taiwan
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2019年 / 59卷 / 03期
关键词
chronic kidney disease; liver transplantation; mTOR inhibitor; renal preservation; urinary biomarkers; CHRONIC KIDNEY-DISEASE; LIPOCALIN NGAL; RAPAMYCIN; TACROLIMUS; EFFICACY; INJURY; STAGE; IMMUNOSUPPRESSION; PROLIFERATION; NEPHROPATHY;
D O I
10.1002/jcph.1334
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mammalian targets of rapamycin inhibitors (mTORIs), including sirolimus and everolimus, are used for minimizing calcineurin inhibitors after liver transplantation. However, head-to-head randomized comparisons of these 2 mTORIs are lacking. We assessed the differences in renoprotection and possible mechanisms between sirolimus and everolimus in liver transplant recipients. For this prospective cohort study, we recruited liver transplant recipients whose regimens were switched from tacrolimus to sirolimus or everolimus at a Taiwan medical center. Serial changes in estimated glomerular filtration rate (eGFR), urinary N-acetyl--D-glucosaminidase, neutrophil gelatinase-associated lipocalin, 8-hydroxy-2-deoxyguanosine, and transforming growth factor-1 during 1 year after mTORI conversion were compared within and between groups. In the 61 patients analyzed, no significant change in eGFR occurred within 12 months after conversion in both mTORI groups. Among patients with baseline eGFR <60 mL/min/1.73 m(2), eGFR improved at 6 months and 1 year after conversion (+12.3 and +12.0 mL/min/1.73 m(2), both P < .05). Urinary N-acetyl--D-glucosaminidase decreased in both sirolimus and everolimus groups at 6 months (-68.7 +/- 137.6 and -62.0 +/- 92.4 U/g creatinine, both P < .05), and the reduction of urinary neutrophil gelatinase-associated lipocalin was significant in the sirolimus group (-4345.1 +/- 7763.5 ng/g creatinine; P < .05). Neither transforming growth factor-1 nor 8-hydroxy-2 '-deoxyguanosine changed significantly. In conclusion, the renoprotective effect of mTORI conversion was significant in liver transplant recipients with renal insufficiency, which was similar for sirolimus and everolimus, in the first year and may be associated with ameliorated tubular injury. Available evidence remains insufficient to determine which mTORI conversion therapy is more effective in renoprotection in the long run.
引用
收藏
页码:326 / 334
页数:9
相关论文
共 50 条
  • [41] The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors
    Lam, P
    Yoshida, A
    Brown, K
    Abouljoud, M
    Bajjoka, I
    Dagher, F
    Moonka, DK
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (06) : 1029 - 1035
  • [42] The effect of calcineurin inhibitors on endothelial function in renal transplant recipients
    Oflaz, H
    Turkmen, A
    Kazancioglu, R
    Kayacan, SM
    Bunyak, B
    Genchallac, H
    Erol, B
    Mercanoglu, F
    Umman, S
    Sever, MS
    [J]. CLINICAL TRANSPLANTATION, 2003, 17 (03) : 212 - 216
  • [43] Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients
    Nadir Alpay
    Abdullah Ozkok
    Yasar Caliskan
    Tulin Akagun
    Suzan Adın Cinar
    Gunnur Deniz
    Muzaffer Sariyar
    Alaattin Yildiz
    [J]. Clinical and Experimental Nephrology, 2014, 18 : 961 - 967
  • [44] Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients
    Alpay, Nadir
    Ozkok, Abdullah
    Caliskan, Yasar
    Akagun, Tulin
    Cinar, Suzan Adin
    Deniz, Gunnur
    Sariyar, Muzaffer
    Yildiz, Alaattin
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (06) : 961 - 967
  • [45] Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus
    Herrero, JI
    Quiroga, J
    Sangro, B
    Pardo, F
    Rotellar, F
    Cienfuegos, JA
    Prieto, J
    [J]. TRANSPLANTATION PROCEEDINGS, 2003, 35 (05) : 1877 - 1879
  • [46] Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus
    Teutonico, A
    Schena, PF
    Di Paolo, S
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (10): : 3128 - 3135
  • [47] CONVERSION TO SIROLIMUS FROM CALCINEURIN INHIBITOR BASED IMMUNOSUPPRESSION IS ASSOCIATED WITH IMPROVEMENT IN RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS WITH RENAL INSUFFICIENCY: SYSTEMATIC REVIEW AND META-ANALYSIS
    Asrani, Sumeet K.
    Leise, Michael D.
    West, Colin P.
    Kim, W. Ray
    [J]. HEPATOLOGY, 2009, 50 (04) : 567A - 568A
  • [48] Linear Growth in Renal Transplant Recipients Is Similar with Sirolimus vs. Calcineurin Inhibitors
    Hymes, L.
    Warshaw, B.
    [J]. PEDIATRIC NEPHROLOGY, 2010, 25 (09) : 1820 - 1821
  • [49] EVEROLIMUS (EVE) IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS CONVERTED FROM CALCINEURIN INHIBITORS (CNI) IMMUNOSUPPRESSION TREATMENT
    Rengel, Manuel
    Abad, Soraya
    Vega, Almudena
    Verdalles, Ursula
    Verde, Eduardo
    [J]. TRANSPLANT INTERNATIONAL, 2011, 24 : 39 - 40
  • [50] Conversion from Calcineurin Inhibitors to Everolimus Resulted in Decrease of Serum TGF-beta and Urinary NGAL in Renal Transplant Recipients.
    Alpay, N.
    Ozkok, A.
    Caliskan, Y.
    Akagun, T.
    Cinar, S.
    Deniz, G.
    Sariyar, M.
    Yildiz, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 545 - 545